Hydrolysis of galactosylceramide is catalyzed by two genetically distinct acid beta-galactosidases.
Two genetically distinct acid beta-galactosidases are apparently involved in the hydrolysis of galactosylceramide in fibroblasts. These beta-galactosidases were activated by different bile salts. The classical galactosylceramidase (galactosylceramidase I, EC 3.2.1.46) was activated by sodium taurocholate, while the other galactosylceramidase (galactosylceramidase II) was activated by sodium cholate. The former was genetically lacking in globoid cell leukodystrophy (GLD) and the latter in GM1 gangliosidosis. Galactosylceramidase II cross-reacted with antibody raised against purified GM1 ganglioside beta-galactosidase (EC 3.2.1.23) from the human placenta. The purified beta-galactosidase had galactosylceramidase II activity, which was competitively inhibited by GM1 ganglioside. Thus, galactosylceramidase II seems to be identical to GM1 ganglioside beta-galactosidase and lactosylceramidase II. Galactosylceramidase II had a very low affinity for galactosylsphingosine. In the galactosylceramide-loading tests using fibroblasts from patients with GLD and GM1 gangliosidosis, both cell lines hydrolyzed the incorporated galactosylceramide, with lower rates than control fibroblasts but higher than the fibroblasts from patients with I-cell disease, in which both galactosylceramidase I and II were deficient. These results indicate that galactosylceramide is hydrolyzed by two genetically distinct beta-galactosidases and explain well that galactosylsphingosine but not galactosylceramide accumulates in the brain of patients with GLD.
D002460:Cell Line; D002554:Cerebrosides / Q000378:metabolism*; D011232:Chemical Precipitation; D019826:Cholic Acid; D002793:Cholic Acids / Q000494:pharmacology; D003429:Cross Reactions; D004789:Enzyme Activation; D005260:Female; D005347:Fibroblasts / Q000201:enzymology; D005677:G(M1) Ganglioside / Q000378:metabolism; D005696:Galactosidases / Q000235:genetics*; D005698:Galactosylceramidase / Q000235:genetics* / Q000378:metabolism; D005699:Galactosylceramides / Q000378:metabolism*; D005733:Gangliosidoses / Q000201:enzymology; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007158:Immunologic Techniques; D007965:Leukodystrophy, Globoid Cell / Q000201:enzymology; D010920:Placenta / Q000201:enzymology; D011247:Pregnancy; D011609:Psychosine / Q000378:metabolism; D013379:Substrate Specificity; D013656:Taurocholic Acid / Q000494:pharmacology; D001616:beta-Galactosidase / Q000235:genetics* / Q000378:metabolism
D002554:Cerebrosides; D002793:Cholic Acids; D005699:Galactosylceramides; D011609:Psychosine; D005677:G(M1) Ganglioside; D013656:Taurocholic Acid; D005696:Galactosidases; D001616:beta-Galactosidase; D005698:Galactosylceramidase; D019826:Cholic Acid